TLR1/2 agonist Pam3Cys-GDPKHPKSF
Term · Oncology and biomedicine · MLC-T-ONC-017195
A vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. Upon administration, TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine.
| Identifier | MLC-T-ONC-017195 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | TLR1/2 agonist XS15; TLR1/2 ligand XS15; Pam3Cys-GDPKHPKSF XS15 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017195",
"term": "TLR1/2 agonist Pam3Cys-GDPKHPKSF",
"field": "Oncology and biomedicine",
"definition": "A vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. Upon administration, TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine.",
"synonyms": [
"TLR1/2 agonist XS15",
"TLR1/2 ligand XS15",
"Pam3Cys-GDPKHPKSF XS15"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/tlr1-2-agonist-pam3cys-gdpkhpksf/"
}
Record 16,419 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.